- Home
- MTNB vs TOVX Comparison
MTNB vs TOVX Comparison
Compare MTNB & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MTNB | TOVX |
|---|---|---|
| Founded | 2013 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1M | 7.3M |
| IPO Year | N/A | 2006 |
Fundamental Metrics
Financial Performance| Metric | MTNB | TOVX |
|---|---|---|
| Price | $0.79 | $0.22 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 31.2K | ★ 2.6M |
| Earning Date | 11-10-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.47 | $0.20 |
| 52 Week High | $3.09 | $2.08 |
Technical Indicators
Market Signals| Indicator | MTNB | TOVX |
|---|---|---|
| Relative Strength Index (RSI) | 35.88 | 42.02 |
| Support Level | $0.76 | $0.21 |
| Resistance Level | $0.98 | $0.24 |
| Average True Range (ATR) | 0.12 | 0.03 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 32.73 | 25.70 |
Price Performance
Historical ComparisonAbout MTNB Matinas Biopharma Holdings Inc.
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.